Osocimab
Osocimab (BAY 1213790), an anti-FXIa antibody (Ki=2.4 nM; EC50=0.2 nM) . FXI inhibition may reduce the risk of thrombosis. Osocimab inhibits thrombin generation, and prolongs activated partial thromboplastin time. Osocimab exhibits anticoagulant effects[1].
Product Specifications
CAS Number
[2056878-75-0]
Product Name Alternative
BAY 1213790
UNSPSC
12352203
Target
Factor Xa
Type
Inhibitory Antibodies
Related Pathways
Metabolic Enzyme/Protease
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/osocimab.html
Purity
98.00
Solubility
10 mM in DMSO
Smiles
[Osocimab]
Molecular Weight
(145.5 kDa)
References & Citations
[1]Schaefer M, et al. Allosteric Inhibition as a New Mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated Form of Coagulation Factor XI. J Mol Biol. 2019 Dec 6;431 (24) :4817-4833.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
GTR15350943 1 Vial
Lentiviral human LKAAEAR1 shRNA (UAS) - Lentiviral human LKAAEAR1 shRNA (UAS, RFP) (100)
Ask
View Details